vimarsana.com
Home
Live Updates
Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS : vimarsana.com
Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS
Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.
Related Keywords
Connecticut ,
United States ,
New Haven ,
Samer Zeidan ,
Daiichi Sankyo ,
States Cerner Enviza ,
Boehringer Ingelheim Incyte ,
Genentech ,
Novartis ,
Myeloid Malignancies At Yale Cancer Center ,
Early Therapeutics Research ,
Amgen ,
Pfizer ,
Clinical Research Team For Leukemias ,
Clinical Research Team ,
Myeloid Malignancies ,
Yale Cancer Center ,
End Results ,
United States Cerner Enviza ,
Charlson Comorbidity Index ,
Medicare Advantage ,
Seattle Genetics ,
Lox Oncology ,
Shattuck Labs ,
Lymphoma Myeloma ,
Oral Decitabine Cedazuridine ,
Parenteral Hypomethylating Agents ,
Intravenous Subcutaneous Hypomethylating Agents ,
Patients With Myelodysplastic Syndrome ,
Bbs ,
vimarsana.com © 2020. All Rights Reserved.